Late Breaking Abstract Parallel Session 1
Nov
2026
Description
Discover and learn more about the latest advancement and breakthroughs in hepatology that are shaping the future of liver disease.
Presentations
2:00 PM
- 2:15 PM
Convention Center - General Session, Hall A
Durability of AHB-137 up to 9 Month Post End-of-Studies in Nucleos(t)ide Analogue Treated Participants with Chronic Hepatitis B: First Long-Term Follow-up Report from the AB-10-8004 Study
Jinlin Hou, MD | Abstract Presenter
2:15 PM
- 2:30 PM
Convention Center - General Session, Hall A
Primary Endpoint Results of ECLIPSE 1: A Randomized Open-Label Phase 3 Study Evaluating Efficacy and Safety of Elebsiran and Tobevibart for Chronic Hepatitis Delta
Nancy S Reau, MD, FAASLD | Abstract Presenter
2:30 PM
- 2:45 PM
Convention Center - General Session, Hall A
Durable pgRNA loss in both HBeAg positive and negative patients treated with PBGENE-HBV supports path towards viral cure
Man-Fung MF Yuen, MD, PhD, DSc | Abstract Presenter
2:45 PM
- 3:00 PM
Convention Center - General Session, Hall A
Simvastatin for Prevention of Hepatic Decompensation or Hepatocellular Carcinoma in Compensated Cirrhosis With Probable Clinically Significant Portal Hypertension: A Phase III Randomized Trial
David E Kaplan, MD, MS, MSc, FAASLD, FACP, AGAF | Abstract Presenter
3:00 PM
- 3:15 PM
Convention Center - General Session, Hall A
Topline Histology Data: Zabopegdutide (DD01), a Dual GLP-1/Glucagon Agonist, Drives Significant Fibrosis Improvement and MASH Resolution at 48 Weeks
Mazen Noureddin, MD, MHSc | Abstract Presenter
3:15 PM
- 3:30 PM
Convention Center - General Session, Hall A
Hepatic Fat Reduction, Lipid-Lowering Effects, and Safety of Thybetador (CS060380), a Next-Generation THR-β Agonist, in MASH: A Phase 2a, Randomized Trial
Jian-Gao Fan, PhD | Abstract Presenter
